SCHEMBL6684775

SCHEMBL6684775

O=C1Nc2ccc(C(=O)NCc3ccc(F)cc3)cc2C(=O)/C1=C\c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK5 P34947 2/20 0.49
CNR1 P21554 1/20 0.47
RAB9A P51151 1/20 0.44
JAK3 P52333 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
PAK4 O96013 2/20 0.42
PPARG P37231 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
LRRK2 Q5S007 1/20 0.42
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835415 1.00 GRK5 (0.49) GRK5CNR1RAB9AJAK3CA1
SCHEMBL6837200 0.93 GRK5 (0.51) GRK5CNR1JAK3PAK4MAOA
SCHEMBL6678879 0.93 GRK5 (0.51) GRK5CNR1JAK3PAK4MAOA
SCHEMBL6835306 0.91 GRK5 (0.49) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6678812 0.91 GRK5 (0.49) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6681004 0.90 GRK5 (0.47) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6685061 0.90 GRK5 (0.47) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6834743 0.89 GRK5 (0.48) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6835291 0.89 GRK5 (0.48) GRK5CNR1JAK3PSEN1PSEN2
SCHEMBL6835242 0.89 GRK5 (0.49) GRK5CNR1JAK3PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 GRK5 474/4885CNR1 3350/4885RAB9A 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.